Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 14,244

Document Document Title
WO/2022/168884A1
The present invention provides a novel cationic lipid having excellent encapsulation and delivery stability of nucleic acid medicines. Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof. (In ...  
WO/2022/166866A1
A class of macrocyclic compounds containing a dihydropyrazine and pyrazine structure, and, in particular, disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.  
WO/2022/166762A1
The present invention relates to a Camptothecin compound having anti-tumor activity, a preparation method therefor, and an application thereof. Specifically, the present invention relates to a compound as shown below or a pharmaceuticall...  
WO/2022/166799A1
Provided are a fused tricyclic cyclin-dependent kinase inhibitor, and a preparation method therefor and a pharmaceutical use thereof. In particular, the structure of the fused tricyclic cyclin-dependent kinase inhibitor is shown in formu...  
WO/2022/167445A1
The present invention provides compounds of formula I, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.  
WO/2022/169948A1
Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and m...  
WO/2022/170268A1
The present invention provides a compound having the structure: [STRUCTURE}, wherein D,E,F,X1, X2 and R1-R14 are as defined herein; a pharmaceutical composition comprising said compound and a pharmaceutically acceptable carrier; and a me...  
WO/2022/169997A1
Various lactam compound that binds Cbl-B, many of which are selective for Cbl-B over C-Cbl, and methods of making and using the same. Representative lactam compounds include molecules falling within the following formulae:  
WO/2022/106469A3
The present invention provides compounds of formula (I), for the treatment of an infection in warm-blooded animal caused by endoparasites, more preferably a helminthic infection, even more preferably a heartworm infection. Exemplary comp...  
WO/2022/166845A1
The present invention relates to a compound of formula (I) capable of inhibiting plasmin activity and having blood coagulation and hemostasis activity, and a pharmaceutically acceptable salt, hydrate, isomer, prodrug, and mixture thereof...  
WO/2022/167457A1
The present invention provides compounds of formula (I), compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.  
WO/2022/163446A1
The present invention addresses the problem of providing a new compound that binds specifically to intracellular and/or extracellular vesicles, a cellular vesicle stain, and a method for fluorescent staining of cellular vesicles. The p...  
WO/2022/162471A1
Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.  
WO/2022/164789A1
The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and ph...  
WO/2022/161479A1
The present invention provides a toxin molecule suitable for an antibody-drug conjugate. In particular, the present invention provides a compound represented by formula (I) below or a pharmaceutically acceptable salt or hydrate thereof. ...  
WO/2022/161443A1
The present application relates to a pyrimidopyran compound, and specifically discloses a compound as represented by formula (III), and a pharmaceutically acceptable salt thereof.  
WO/2022/161480A1
The present invention relates to a substituted bicyclo-aromatic heterocyclic amine inhibitor, a preparation method therefor, and the use thereof. Specifically, a compound of the present invention has a structure as represented by formula...  
WO/2022/159980A1
Disclosed herein are compounds (e.g., pyrrole compounds, carboxy pyrroles, etc.), including pharmaceutical compositions that include one or more of such compounds (e.g., carboxy pyrroles). Also disclosed are methods of making carboxy pyr...  
WO/2022/155860A1
The disclosure provides at compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating diseases, disorders of conditions mediated by the signaling of formyl peptide receptor 1 (FPR1).  
WO/2022/157599A1
A novel organic compound is provided, specifically, a novel organic compound effective in heightening element characteristics is provided. This organic compound is represented by general formula (G1). In general formula (G1), at least on...  
WO/2022/157271A1
The present invention relates to compounds of formula (I), which are modulators of sortilin activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment...  
WO/2022/156765A1
Disclosed is a pyrazolopyrazine-linked tricyclic compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound has inhibitory activity on protein tyrosine phosphatase SHP2 and can be used to treat diseas...  
WO/2022/156761A1
Provides compounds represented by Formula(I): wherein R 3, R 8c, R 8d, A, A 1, A 2, A 3, A 4, E, E 1, L, Q, Z, and (II) are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of For...  
WO/2022/159981A1
Disclosed herein are triazine compounds (e.g., triazines and pyrazole triazines) and methods of treating diseases and/or conditions (e.g., inflammation) with the triazine compounds disclosed herein. In several embodiments, the disclosed ...  
WO/2022/153268A1
This invention relates to pharmaceutically acceptable tryptamine analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.  
WO/2022/152705A1
Compounds of Formula (I) wherein R1, R3, R11, R12, X, Y1, Y2, Y3, Y4 and formula (II) are as defined in the description. Medicaments.  
WO/2022/150917A1
The invention relates to crystalline forms of Alpha-1062 gluconate (scheme I: (I)). In one aspect, the invention relates to a crystalline solid form of Alpha-1062 gluconate (Form A), wherein said crystalline form has prominent peaks at 3...  
WO/2022/152233A1
Provided are compounds of Formula (I) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as G12C inhibitors, and a pharmaceutical composition comprising the same.  
WO/2022/149856A1
The present invention provides a compound, having a specific chemical structure, having a Bruton's tyrosine kinase (BTK)-inhibiting activity, or a pharmaceutically acceptable salt thereof. The present invention provides a composition com...  
WO/2022/149757A1
The present invention relates to a novel heterocyclic compound and an organic light-emitting device comprising same. The heterocyclic compound, according to the present invention, is a polycyclic heterocyclic compound which has a condens...  
WO/2022/148421A1
Provided are bridged compounds as well as their compositions and methods of use. The compounds disclosed herein inhibit KRAS G12D activity and are useful in the treatment of various diseases including cancer.  
WO/2022/150345A1
The present disclosure describes, in part, methods for diagnosing and/or treating autoimmune diseases using a compound capable of inhibiting eHsp90.  
WO/2022/144423A1
The invention relates to a chemical compound of general formula (I), to an optoelectronic component containing such a compound, and to the use of such a compound in an optoelectronic component.  
WO/2022/143489A1
A tricyclic compound having the structure represented by general formula (I), a pharmaceutical composition thereof, a preparation method therefor and the use thereof in the prevention and treatment of a variety of diseases caused by toxi...  
WO/2022/143533A1
Disclosed are a quinazoline derivative of formula (I), a pharmaceutical composition containing the derivative and the use thereof in medicine, in particular the use as an SOS1 inhibitor and the use in the preparation of a medicament for ...  
WO/2022/139167A1
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic layer.  
WO/2022/140456A1
This disclosure is in the field of medicinal chemistry, and relates to a new class of small-molecules having the Formula I, or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer, a mixture of enantiomers, a mixture o...  
WO/2022/137085A1
The present disclosure relates to a compound of Formula (I): (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein R1 through R8 are as defined herein, and methods of making and using th...  
WO/2022/138944A1
The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the f...  
WO/2022/133816A1
The present invention provides a porphyrin compound and a preparation method therefor and use thereof, and a pharmaceutical composition using the porphyrin compound as an active ingredient. The porphyrin compound has a novel and adjustab...  
WO/2022/134074A1
An organic electroluminescent device, a display panel, a display device and a light-emitting device are provided, belonging to the technical field of display. The organic electroluminescent device comprises an anode, an electron blocking...  
WO/2022/140169A1
Invented are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising c...  
WO/2022/138987A1
The present invention provides a compound exhibiting a coronavirus 3CL protease inhibitory effect and pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the same. Further provided are crystals that are...  
WO/2021/122415A9
The present invention covers furoindazole compounds of general formula (I): in which (I) are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions ...  
WO/2022/135546A1
The present invention relates to a spirocyclic compound, represented by formula (I), as a KRAS-G12C inhibitor, which can be used in the preparation of a drug for treating KRAS G12C-mediated tumors.  
WO/2022/138791A1
The purpose of the present invention is to provide a medicine for the prevention and/or treatment of a disease caused by activation of an EP2 receptor, said medicine containing, as an active ingredient, a compound having an antagonistic ...  
WO/2022/139180A1
The present invention provides a heterocyclic compound represented by chemical formula 1 and an organic light-emitting device comprising same.  
WO/2022/139228A1
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic material layer.  
WO/2022/139360A1
The present invention relates to a novel compound with excellent electron transport, light emission, and heat stability, and to an organic electroluminescent device that includes the compound in at least one organic material layer to hav...  
WO/2022/140504A1
Provided herein are antibody-drug conjugates, for example, a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms o...  

Matches 1 - 50 out of 14,244